Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to
evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when
given with fixed dose nivolumab in patients with relapsed or refractory classical Hodgkin
lymphoma (cHL).